PDF(Pubmed)
Abstract：
UNASSIGNED: Since the European approval of CDK4/6 inhibitors in 2016, the treatment of patients with hormone-receptor-positive, HER2-negative metastatic breast cancer has changed significantly. Compared with chemotherapy, endocrine-based therapy has different treatment regimens and is associated with new side effects. Oral therapy aims for optimal drug efficacy and long treatment times while maintaining maximum independence and quality of life resulting in the conservation of medical staff resources.
UNASSIGNED: A monocentric analysis of therapy preferences of practitioners (25 nurses and physicians) and patients (11 on endocrine monotherapy, 17 on endocrine-based therapy, and 14 on intravenous chemotherapy) was performed using specific questionnaires. Preferences were assessed using a four-point Likert scale or bidirectional response options.
UNASSIGNED: All patients were highly supportive of oral therapy (mean agreement score on the Likert scale 1.3, p < 0.001 vs. all other options) and a consultation interval of 4 weeks (2.0, p = 0.015 vs. 3 weeks). Practitioners also preferred oral therapy (1.4) and visits every 4 weeks (1.6). In general, patients on oral therapies reported higher compatibility of their therapy with daily life than patients on chemotherapy (1.6 and 1.7 vs. 2.6, p = 0.006). Outpatient oncology is the main source of information for all patients, mainly in case of side effects (2.0) and open questions (1.8). Regarding oral antitumor therapy regimens, patients do not show a significant preference for a specific regimen, while practitioners prefer a continuous regimen (1.6) over a 21/7 regimen (21 days on and 7 days off therapy, 2.5). Patients are likely to accept mild side effects (e.g., neutropenia, diarrhea, polyneuropathy, fatigue) and would still adhere to their initial choice of regimen (continuous or 21/7). Only when side effects occur with a severity of CTCAE grade 3 do patients prefer the regimen in which the side effects occur for a shorter period of time.
UNASSIGNED: Patients and practitioners prefer oral antitumor therapy-both continuous and 21/7 regimens-over other application forms. Patient education and proper therapy management, supported by additional tools, contribute to the specific management of side effects and high adherence. This allows quality of life to be maintained during long-term therapy with CDK4/6 inhibitors in patients with metastatic breast cancer.
UNASSIGNED: A monocentric analysis of therapy preferences of practitioners (25 nurses and physicians) and patients (11 on endocrine monotherapy, 17 on endocrine-based therapy, and 14 on intravenous chemotherapy) was performed using specific questionnaires. Preferences were assessed using a four-point Likert scale or bidirectional response options.
UNASSIGNED: All patients were highly supportive of oral therapy (mean agreement score on the Likert scale 1.3, p < 0.001 vs. all other options) and a consultation interval of 4 weeks (2.0, p = 0.015 vs. 3 weeks). Practitioners also preferred oral therapy (1.4) and visits every 4 weeks (1.6). In general, patients on oral therapies reported higher compatibility of their therapy with daily life than patients on chemotherapy (1.6 and 1.7 vs. 2.6, p = 0.006). Outpatient oncology is the main source of information for all patients, mainly in case of side effects (2.0) and open questions (1.8). Regarding oral antitumor therapy regimens, patients do not show a significant preference for a specific regimen, while practitioners prefer a continuous regimen (1.6) over a 21/7 regimen (21 days on and 7 days off therapy, 2.5). Patients are likely to accept mild side effects (e.g., neutropenia, diarrhea, polyneuropathy, fatigue) and would still adhere to their initial choice of regimen (continuous or 21/7). Only when side effects occur with a severity of CTCAE grade 3 do patients prefer the regimen in which the side effects occur for a shorter period of time.
UNASSIGNED: Patients and practitioners prefer oral antitumor therapy-both continuous and 21/7 regimens-over other application forms. Patient education and proper therapy management, supported by additional tools, contribute to the specific management of side effects and high adherence. This allows quality of life to be maintained during long-term therapy with CDK4/6 inhibitors in patients with metastatic breast cancer.
摘要：
■自2016年欧洲批准CDK4/6抑制剂以来，激素受体阳性患者的治疗，HER2阴性转移性乳腺癌发生了显著变化。与化疗相比,基于内分泌的治疗有不同的治疗方案,并且与新的副作用相关.口服治疗旨在获得最佳的药物疗效和长的治疗时间，同时保持最大的独立性和生活质量，从而节省医务人员资源。
■对从业人员（25名护士和医师）和患者（11名内分泌单一疗法，17关于内分泌治疗，和14次静脉化疗）使用特定问卷进行。使用四点李克特量表或双向反应选项评估偏好。
■所有患者均高度支持口服治疗（李克特量表的平均一致评分1.3，p<0.001vs.所有其他选项)和4周的咨询间隔(2.0，p=0.015vs.3周）。从业者还首选口服治疗（1.4）和每4周就诊（1.6）。总的来说,口服治疗的患者报告其治疗与日常生活的相容性高于化疗患者(1.6和1.7vs.2.6，p=0.006）。肿瘤科门诊是所有患者的主要信息来源,主要是在副作用（2.0）和开放性问题（1.8）的情况下。关于口服抗肿瘤治疗方案，患者对特定方案没有明显的偏好，虽然从业者更喜欢连续方案（1.6）而不是21/7方案（21天和7天治疗，2.5).患者可能会接受轻微的副作用(例如，中性粒细胞减少症,腹泻,多发性神经病,疲劳)，并且仍然坚持他们最初选择的方案(连续或21/7)。只有当出现严重程度为CTCAE3级的副作用时，患者才更喜欢在较短的时间内出现副作用的方案。
■与其他应用形式相比，患者和医生更喜欢口服抗肿瘤治疗-连续和21/7方案。患者教育和适当的治疗管理，由其他工具支持，有助于副作用的具体管理和高依从性。这允许在转移性乳腺癌患者的CDK4/6抑制剂的长期治疗期间维持生活质量。
■对从业人员（25名护士和医师）和患者（11名内分泌单一疗法，17关于内分泌治疗，和14次静脉化疗）使用特定问卷进行。使用四点李克特量表或双向反应选项评估偏好。
■所有患者均高度支持口服治疗（李克特量表的平均一致评分1.3，p<0.001vs.所有其他选项)和4周的咨询间隔(2.0，p=0.015vs.3周）。从业者还首选口服治疗（1.4）和每4周就诊（1.6）。总的来说,口服治疗的患者报告其治疗与日常生活的相容性高于化疗患者(1.6和1.7vs.2.6，p=0.006）。肿瘤科门诊是所有患者的主要信息来源,主要是在副作用（2.0）和开放性问题（1.8）的情况下。关于口服抗肿瘤治疗方案，患者对特定方案没有明显的偏好，虽然从业者更喜欢连续方案（1.6）而不是21/7方案（21天和7天治疗，2.5).患者可能会接受轻微的副作用(例如，中性粒细胞减少症,腹泻,多发性神经病,疲劳)，并且仍然坚持他们最初选择的方案(连续或21/7)。只有当出现严重程度为CTCAE3级的副作用时，患者才更喜欢在较短的时间内出现副作用的方案。
■与其他应用形式相比，患者和医生更喜欢口服抗肿瘤治疗-连续和21/7方案。患者教育和适当的治疗管理，由其他工具支持，有助于副作用的具体管理和高依从性。这允许在转移性乳腺癌患者的CDK4/6抑制剂的长期治疗期间维持生活质量。
